Ultragenyx disclosed failure of two phase‑3 trials in brittle‑bone disease and announced plans for major cost reductions. The company said interim analyses did not meet efficacy thresholds and will pivot to preserve runway while reassessing pipeline prioritization and R&D spend. Management signaled an overhaul of resource allocation and increased focus on programs with clearer regulatory paths. The cuts reflect growing investor pressure on mid‑cap biotechs to balance high R&D costs with near‑term readouts and raise the prospect of program terminations or asset sales as part of restructuring.